The entity and concept of immune therapy against chronic infections and cancers is still elusive. Credible preclinical studies and clinical trials
are scare in this field due to improper understating about cellular and molecular mechanism of these diseases. In addition, immune interventional
strategies against these diseases have not been properly formulated. A sketch about immune pathogenesis of these diseases and interventional
strategies has been formulated in this communication.
Zanetti AR, Zappa A. Emerging and re-emerging infections at the turn of the millennium. Haemophilia 2010;16(S1):7-12
Prevention and management of chronic disease: A litmus test for health-systems strengthening in low-income and middle-income countries. Lancet 2010; 20;376:1785-97 3. Liaw YF. Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia. J Hepatol 2009;51:403-07
Treatment of hepatitis B virus-infected patients: Utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14
Future aspects of therapy for hepatitis B virus infection: Value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol (in press)
Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep) 2008;174:1-671
Antiviral therapy for adults with chronic hepatitis B: A systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009;150:111–24
Engineering immune therapy against hepatitis B virus: Hepatol Res 2007;37(S):S351-56
Safety, efficacy and immunogenecity of a therapeutic vaccine containing HBsAg and HBcAg by nasal route in patients with chronic hepatitis B. J Hepatol 2010;52:392.
